GNMK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GNMK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-26), GenMark Diagnostics's share price is $24.04. GenMark Diagnostics's Tangible Book per Share of Dec. 2020 for the quarter that ended in Dec. 2020 was $1.30. Hence, GenMark Diagnostics's Price to Tangible Book Ratio of today is 18.54.
The historical rank and industry rank for GenMark Diagnostics's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, GenMark Diagnostics's highest Price to Tangible Book Ratio was 37.30. The lowest was 8.95. And the median was 11.23.
A closely related ratio is called PB Ratio. As of today, GenMark Diagnostics's share price is $24.04. GenMark Diagnostics's Book Value per Sharefor the quarter that ended in Dec. 2020 was $1.31. Hence, GenMark Diagnostics's P/B Ratio of today is 18.37.
The historical data trend for GenMark Diagnostics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMark Diagnostics Annual Data | |||||||||||||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | 16.06 | 3.35 | 8.66 | 27.02 | 11.26 |
GenMark Diagnostics Quarterly Data | ||||||||||||||||||||
Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 27.02 | 21.57 | 11.67 | 10.89 | 11.26 |
For the Medical Devices subindustry, GenMark Diagnostics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, GenMark Diagnostics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where GenMark Diagnostics's Price-to-Tangible-Book falls into.
GenMark Diagnostics's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Dec. 2020 ) |
= | 24.04 | / | 1.297 | |
= | 18.54 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of GenMark Diagnostics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Tyler Jensen | officer: SVP, Engineering and Tech Dev | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Christine Shaw | officer: VP, Assay Development | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Alan Baer Maderazo | officer: VP, Qual, Reg, & Clin Affairs | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Michael Gleeson | officer: SVP, Corp. Accounts | 5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008 |
Sarah Hollis Winkler | officer: VP, Human Resources | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Michael John Harkins | officer: SVP, Sales | 5964 LA PLACE COURT CARLSBAD CA 92008 |
John Frederick Ek | officer: Chief Financial Officer | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
Scott Mendel | director, officer: President & CEO | 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008 |
Eric Stier | officer: SVP & General Counsel | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Brian Andrew Mitchell | officer: SVP, Operations | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Daryl Faulkner | director | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
Michael Kagnoff | director | DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121 |
Lisa M. Giles | director | DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606 |
Kevin C Oboyle | director | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
James Fox | director | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
From GuruFocus
By Marketwired Marketwired • 07-30-2020
By Marketwired Marketwired • 09-15-2020
By GuruFocus Research GuruFocus Editor • 08-14-2020
By Marketwired Marketwired • 10-09-2020
By Marketwired Marketwired • 01-12-2021
By GuruFocus Research GuruFocus Editor • 05-03-2021
By Marketwired Marketwired • 02-17-2021
By GlobeNewswire GlobeNewswire • 10-14-2020
By Marketwired Marketwired • 07-22-2020
By Marketwired Marketwired • 07-08-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.